Physician profile
Benjamin Eric Stephens
NPI 1902291131
$2,242.28
in general payments reported to CMS, 2019-2025
29 companies · $367 in 2025
The $367 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166 · 2020: $37.46 · 2021: $46.08 · 2022: $594 · 2023: $228 · 2024: $804 · 2025: $367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,398.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fujifilm Sonosite, INC. | $447.52 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $321.40 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $229.30 | 2022-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.59 | 2019-2025 | Ofev |
| Amgen INC. | $129.13 | 2024-2025 | Tezspire |
| Insmed, INC. | $102.61 | 2019-2020 | |
| Genzyme Corporation | $96.87 | 2024 | |
| Abiomed | $91.17 | 2025 | |
| United Therapeutics Corporation | $83.29 | 2023-2024 | Tyvaso |
| Ani Pharmaceuticals, INC. | $62.44 | 2024 | Purified Cortrophin Gel |
| Mylan Specialty L.P. | $56.11 | 2019-2024 | Yupelri |
| Electromed, INC. | $52.78 | 2019-2024 | Smartvest |
| Regeneron Healthcare Solutions, INC. | $48.07 | 2024-2025 | Dupixent |
| Abbvie INC. | $46.70 | 2025 | |
| Fisher Scientific Company L.L.C. | $46.08 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $37.97 | 2024 | Xarelto |
| Viatris Specialty LLC | $30.69 | 2025 | Yupelri |
| La Jolla Pharmaceutical Company | $28.83 | 2024 | Giapreza |
| Tactile Systems Technology INC | $28.68 | 2024-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Grifols USA, LLC | $23.72 | 2024 | Prolastin-C Liquid |
| Mallinckrodt Hospital Products INC. | $22.07 | 2025 | Acthar |
| Inogen, INC. | $18.81 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.86 | 2024 | Glassia |
| Gilead Sciences, INC. | $16.87 | 2023 | |
| Philips North America LLC | $16.83 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.05 | 2024 | |
| Azurity Pharmaceuticals, INC. | $15.36 | 2024 | Horizant |
| Baxter Healthcare | $12.97 | 2022 | |
| Merck Sharp & Dohme LLC | $12.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.